TW201821062A - 溴結構域抑制劑 - Google Patents

溴結構域抑制劑 Download PDF

Info

Publication number
TW201821062A
TW201821062A TW106136093A TW106136093A TW201821062A TW 201821062 A TW201821062 A TW 201821062A TW 106136093 A TW106136093 A TW 106136093A TW 106136093 A TW106136093 A TW 106136093A TW 201821062 A TW201821062 A TW 201821062A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
cyclopropylmethoxy
polymer
compound
methylisoquinolin
Prior art date
Application number
TW106136093A
Other languages
English (en)
Chinese (zh)
Inventor
胡安曼努爾 貝坦科特
傑佛瑞艾倫 史塔福德
萊恩 史丹斯菲爾德
詹姆士馬文 維爾
Original Assignee
美商塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商塞爾基因定量細胞研究公司 filed Critical 美商塞爾基因定量細胞研究公司
Publication of TW201821062A publication Critical patent/TW201821062A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW106136093A 2016-10-20 2017-10-20 溴結構域抑制劑 TW201821062A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20
US62/410,756 2016-10-20

Publications (1)

Publication Number Publication Date
TW201821062A true TW201821062A (zh) 2018-06-16

Family

ID=62019669

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106136093A TW201821062A (zh) 2016-10-20 2017-10-20 溴結構域抑制劑

Country Status (7)

Country Link
EP (1) EP3528810A4 (enExample)
JP (3) JP7129973B2 (enExample)
CN (1) CN110099685A (enExample)
AR (1) AR109859A1 (enExample)
AU (1) AU2017345468B2 (enExample)
TW (1) TW201821062A (enExample)
WO (1) WO2018075796A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
JP7434274B2 (ja) * 2018-07-23 2024-02-20 セルジーン・クオンティセル・リサーチ・インコーポレイテッド ブロモドメイン阻害剤の合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
KR20160037201A (ko) * 2013-08-06 2016-04-05 온코에틱스 게엠베하 Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법
WO2015031824A1 (en) * 2013-08-30 2015-03-05 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors
PE20161065A1 (es) * 2013-10-18 2016-11-19 Celgene Quanticel Res Inc Inhibidores de bromodominio
US9757385B2 (en) * 2013-11-27 2017-09-12 Merck Sharp & Dohme Corp. Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
CN105732624B (zh) * 2016-01-28 2019-08-02 中国药科大学 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途

Also Published As

Publication number Publication date
JP2022095897A (ja) 2022-06-28
JP2024056905A (ja) 2024-04-23
JP7129973B2 (ja) 2022-09-02
AU2017345468A1 (en) 2019-06-06
EP3528810A1 (en) 2019-08-28
JP2019535671A (ja) 2019-12-12
AR109859A1 (es) 2019-01-30
WO2018075796A1 (en) 2018-04-26
AU2017345468B2 (en) 2022-06-02
EP3528810A4 (en) 2020-06-17
CN110099685A (zh) 2019-08-06

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
TWI828817B (zh) 用於治療或預防痛風或高尿酸血症之化合物晶型
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
JP2024056905A (ja) ブロモドメイン阻害剤
CA3140412A1 (en) Compound for treating gout or hyperuricemia
JP2022507251A (ja) P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用
US20230301983A1 (en) Bromodomain inhibitor
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP2020532522A (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia